Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 25, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 25, 2023 Category: Hematology Source Type: research

Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study
Patients with prior allogeneic stem cell transplant (alloSCT) are typically excluded from trials of chimeric antigen receptor (CAR) T cell therapies, because their engineered cells may include allogeneic T cells. Ciltacabtagene autoleucel (cilta-cel) demonstrated early, deep, durable responses and manageable safety in heavily pretreated relapsed/refractory multiple myeloma patients. We retrospectively analyzed patients who received alloSCT prior to cilta-cel in CARTITUDE-1. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 22, 2023 Category: Hematology Authors: Myo Htut, Binod Dhakal, Adam D. Cohen, Thomas Martin, Jesus G Berdeja, Saad Z. Usmani, Mounzer Agha, Carolyn C. Jackson, Deepu Madduri, William Deraedt, Enrique Zudaire, Tzu-min Yeh, Xiaoying Xu, Lida Pacaud, Muhammad Akram, Sundar Jagannath Tags: Original Study Source Type: research

Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia
Early mortality is a historical measure of quality of care incorporated into many quality measure algorithms that mostly account for patient co-morbidities but do not incorporate disease characteristics and treatment status which independently increase early mortality. This is particularly significant in leukemia, especially in the refractory and salvage settings. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 22, 2023 Category: Hematology Authors: Koji Sasaki, Farhad Ravandi, Courtney DiNardo, Mary Alma Welch, Tapan Kadia, Hagop Kantarjian Tags: Original Study Source Type: research

Updates in The Management of Primary Mediastinal B Cell Lymphoma
Primary mediastinal B cell lymphoma is considered a distinct pathology according to the WHO classification of lymphoid malignancies. Patients have a better prognosis after the addition of Rituximab to anthracycline-based chemotherapy. The role of consolidative radiotherapy is controversial after the approval of dose adjusted R-EPOCH and the selection of patients to undergo radiotherapy is based on end-of-therapy PET CT. In the relapsed/refractory setting, new approved drugs and other under investigation have improved patient's outcome. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 21, 2023 Category: Hematology Authors: Charbel Soueidy, Hampig Raphael Kourie Tags: Review Article Source Type: research

Descriptive Analysis and Factors Influencing Survival in Patients with Primary Cutaneous Gamma-Delta T Cell Lymphoma. A Retrospective National Cancer Database Study.
Gamma delta T cells gives rise to a rare malignancy called Primary cutaneous Gamma-Delta T cell lymphoma (PCGDTCL). From the National Cancer Database (NCDB), 110 (0.015%) patients with PCGDTCL were identified. Males aged>60 years were the commonest cohort. Caucasian race was the most common (Caucasian:79.09%, African American:16.36%). Most patients were diagnosed at stage 1 (52.33%), followed by stage 4 (30.23%). On analyzing income categories, (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 21, 2023 Category: Hematology Authors: Prashanth Ashok Kumar, Abirami Sivapiragasam, Dongliang Wang, Danning Huang, Teresa Gentile Source Type: research

The influence of religiosity and spirituality on the quality of life of patients with multiple myeloma
The relevance of religion and spirituality for medicine is nowhere clearer than in the care of seriously ill and dying patients.1 Today, cancer is the second most prevalent disease and the leading cause of death after cardiovascular disease. Epidemiological projections indicate that cancer is expected to become the most common cause of mortality worldwide in the next few decades. The consequence is an increasing demand for the development of medical care, but also the need for research in the fields of medicine and health psychology in cancer patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 19, 2023 Category: Hematology Authors: Weronika Lebowa, Jacek Prusak, Marlena Le śniak, Jakub Wasiewicz, Artur Jurczyszyn Tags: Original Study Source Type: research

Loss of CD34+ cells and effect of the number of viable cryopreserved CD34+ cells in the infused blood grafts on hematologic recovery, progression-free survival and overall survival in NHL patients after autologous stem cell transplantation
This post-hoc study aimed to find out factors affecting graft viable CD34+ cell loss during processing and cryopreservation in 129 non-Hodgkin lymphoma (NHL) patients receiving autologous stem cell transplantation (auto-SCT) and the impact of a low ( (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 17, 2023 Category: Hematology Authors: Anu Partanen, Antti Turunen, Jaakko Valtola, Marja Py örälä, Outi Kuittinen, Hanne Kuitunen, Kaija Vasala, Karri Penttilä, Taru Kuittinen, Pentti Mäntymaa, Jukka Pelkonen, Esa Jantunen, Ville Varmavuo Tags: Original Study Source Type: research

The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma
Higher yields of stem-cells collected to support autologous transplantation may predict for improved outcomes in multiple myeloma (MM). We reviewed 621 patients who underwent autologous transplantation for MM and in contrast to some previous data found that the most efficient mobilizers had worse progression-free survival. This association may reflect differences in many treatment variables related to both the collection yields and myeloma outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2023 Category: Hematology Authors: Eyal Lebel, Katherine Lajkosz, Esther Masih-Khan, Donna Reece, Suzanne Trudel, Rodger Tiedemann, Anca Prica, Vishal Kukreti, Christine Chen Tags: Original Study Source Type: research

The impact of CD34+  cell collection yields for autologous transplant  on survival outcomes in multiple myeloma  
According to previous data, higher yields of stem-cells collected to support autologous transplantation may predict for improved outcomes. We aimed to assess the association between high stem-cells  collection and survival outcomes in multiple myeloma (MM)   (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2023 Category: Hematology Authors: Eyal Lebel, Katherine Lajkosz, Esther Masih-Khan, Donna Reece, Suzanne Trudel, Rodger Tiedemann, Anca Prica, Vishal Kukreti, Christine Chen Tags: Original Study Source Type: research

Clinicopathologic Features of Cutaneous T-cell Lymphomas with Extracutaneous Metastasis: A Case Series
In advanced stages, Cutaneous T-cell lymphomas (CTCL) can metastasize to extracutaneous regions. CTCL with metastasis exhibits unique clinicopathologic characteristics. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2023 Category: Hematology Authors: Haiming Tang, Nana Matsumoto, Francine Foss, Mina Xu, Aadil Ahmed Tags: Original Study Source Type: research

SOHO State of the Art Updates and Next Questions | Immunotherapeutic Options for Patients with Mantle Cell Lymphoma Who Progress on BTK Inhibitors
Mantle cell lymphoma is a challenging subtype of B-cell non-Hodgkin lymphoma treat characterized by its aggressive nature and propensity for relapse or refractory (R/R) disease for many patients. The introduction of Bruton's tyrosine kinase inhibitors has significantly improved the outcomes for patients with R/R MCL, but a considerable proportion of patients eventually experience disease progression or develop resistance to these agents. In recent years, immunotherapeutic approaches have emerged as promising treatment options. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 14, 2023 Category: Hematology Authors: Rahul K Nayak, Drew Gerber, Chen Zhang, Jonathon B. Cohen Source Type: research

Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review
We performed a systematic review of the literature investigating the demographic and insurance-related factors linked to disparities in multiple myeloma (MM) care patterns in the United States from 2003 to 2021.Forty-six observational studies were included. Disparities in MM care patterns were reported based on patient race in 76% of studies (34 out of 45 that captured race as a study variable), ethnicity in 60% (12 out of 20), insurance in 77% (17 out of 22), and distance from treating facility, urbanicity, or geographic region in 62% (13 out of 21). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 13, 2023 Category: Hematology Authors: Hamlet Gasoyan, Mark A. Fiala, Michelle Doering, Ravi Vij, Michael Halpern, Graham A. Colditz Tags: Review Article Source Type: research

Disparities in Time to Diagnosis Among Patients with Multiple Myeloma
Background: Multiple myeloma (MM) is one of the most diagnosed hematologic malignancies in the United States. Despite improvements in therapy, health disparities persist among patients with MM. Here, we aim to determine whether there are disparities in time to diagnosis (TTD) among MM patients with regard to income, race/ethnicity, and gender.Patients: Patients with a monoclonal protein detected in the serum and/or urine and a subsequent bone marrow biopsy confirmed diagnosis of MM were included in the study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2023 Category: Hematology Authors: Lin Olivia M, Paine Dana, Gramling Esther, Menon Manoj Tags: Original Study Source Type: research

Cost of Disease Progression in Diffuse Large B-cell Lymphoma After Frontline Treatment With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
We present results from two independent, retrospective, real-world cohort analyses to determine the cost of disease progression after first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 9, 2023 Category: Hematology Authors: John M. Burke, Anthony Masaquel, Rongrong Wang, Farah Hossain, Jia Li, Summera Qiheng Zhou, Carmen D. Ng, Matthew Matasar Tags: Original Study Source Type: research